Literature DB >> 8864751

In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector.

P B Arbuthnot1, M P Bralet, C Le Jossic, J F Dedieu, M Perricaudet, C Bréchot, N Ferry.   

Abstract

Recombinant adenoviruses are widely used for the transfer of foreign genes into various mammalian cells. However, the utilization of these vectors for cancer gene therapy requires the specific and efficient expression of the transferred gene in tumor cells. To obtain targeted expression in hepatoma cells, we constructed recombinant adenoviral vectors containing transcriptional elements from either the rat alpha-fetoprotein (AFP) or the human insulin-like growth factor II (IGFII) genes driving expression of the nuclear beta-galactosidase gene (nls lacZ). In vitro infection revealed that the AFP but not the IGFII transcriptional regulatory sequence controlled nls lacZ expression specifically in hepatoma cells. The same specificity was obtained in vivo in subcutaneous human hepatic tumors generated by engraftment of Huh7 hepatoma cells in nude mice as well as in primary liver tumors developed in rats and mice. No marker gene expression was detectable after AFP-nls lacZ gene transfer to normal rat liver parenchyma despite evidence for the presence of DNA encoding the nls lacZ gene. However, in vivo experiments with primary liver tumors in rats and mice also revealed that primary hepatoma cells were poorly infected by adenoviral vectors. Peritumoral and normal tissues were infected efficiently by adenoviral vectors. We conclude that hepatoma cell-specific expression of a transgene can be achieved with AFP regulatory sequences but that adenoviral vectors may not be the preferable vector for transferring genes in vivo in primary liver tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864751     DOI: 10.1089/hum.1996.7.13-1503

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

1.  Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo.

Authors:  S Kim; H Lin; E Barr; L Chu; J M Leiden; M S Parmacek
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma.

Authors:  Shao-Ying Lu; Yan-Fang Sui; Zeng-Shan Li; Cheng-En Pan; Jing Ye; Wen-Yong Wang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

3.  Gene therapy vectors harboring AFP regulatory sequences. Preparation of an adenoviral vector.

Authors:  S Kaneko; T Tamaoki
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

Review 4.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

5.  Pharmacogenetic selection of transplanted human hepatocytes in immunocompetent rats.

Authors:  Martina Smolic; Catherine H Wu; Shilpa Madadi; Nidhi Gupta; Robert Smolic; Marcy Coash; Jeanette Smith; George Y Wu
Journal:  J Dig Dis       Date:  2012-11       Impact factor: 2.325

6.  DNA/amphiphilic block copolymer nanospheres promote low-dose DNA vaccination.

Authors:  Dorian McIlroy; Benoît Barteau; Jeannette Cany; Peggy Richard; Clothilde Gourden; Sophie Conchon; Bruno Pitard
Journal:  Mol Ther       Date:  2009-05-05       Impact factor: 11.454

7.  Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma.

Authors:  Kang-Jian Zhang; Jing Qian; Shi-Bing Wang; Yi Yang
Journal:  J Biomed Sci       Date:  2012-02-09       Impact factor: 8.410

Review 8.  New Tools for Molecular Therapy of Hepatocellular Carcinoma.

Authors:  Alessandra Marchetti; Francesca Bisceglia; Angela M Cozzolino; Marco Tripodi
Journal:  Diseases       Date:  2015-10-30

9.  Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.

Authors:  Wei Cheng; Chia-Jen Tseng; Tom T C Lin; I Cheng; Hung-Wei Pan; Hey-Chi Hsu; Yu-May Lee
Journal:  Carcinogenesis       Date:  2008-04-15       Impact factor: 4.944

10.  Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer.

Authors:  Eiji Toyoda; Ryuichiro Doi; Kazuhiro Kami; Tomohiko Mori; Daisuke Ito; Masayuki Koizumi; Atsushi Kida; Kazuyuki Nagai; Tatsuo Ito; Toshihiko Masui; Michihiko Wada; Masatoshi Tagawa; Shinji Uemoto
Journal:  J Exp Clin Cancer Res       Date:  2008-08-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.